Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy
Michael R. Shurin, Viktor Umansky
Michael R. Shurin, Viktor Umansky
Published May 2, 2022
Citation Information: J Clin Invest. 2022;132(9):e159473. https://doi.org/10.1172/JCI159473.
View: Text | PDF
Commentary Article has an altmetric score of 5

Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy

  • Text
  • PDF
Abstract

Tumor-associated hypoxia plays an important role in carcinogenesis and metastasis. The expression, activation, and stabilization of hypoxia-inducible transcription factors (HIFs) support malignant cell survival, proliferation, plasticity, and motility. Hypoxia also upregulates the expression of programmed cell death ligand 1 (PD-L1) in malignant and immune regulatory cells. Therefore, the combination of HIF inhibitors and checkpoint inhibitors (CPIs) is promising for boosting antitumor immunity and diminishing malignant cell plasticity and therapy resistance. In this issue of the JCI, Salman et al. report the development of a specific agent that inhibited HIF-1/2–mediated gene expression in tumor cells and suppressed tumor growth. Bailey, Liu, et al. in this issue demonstrate that targeting HIF-1α abrogated PD-L1–mediated immune evasion by suppressing PD-L1 expression on malignant and myeloid regulatory cells, causing tumor rejection. These findings suggest that targeting the HIF/PD-L1 axis with specific HIF inhibitors should improve the safety and efficacy of CPIs for cancer therapy.

Authors

Michael R. Shurin, Viktor Umansky

×

Figure 1

Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy.

Options: View larger image (or click on image) Download as PowerPoint
Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and the...
A majority of solid tumors develop hypoxia because of chaotic vascularization leading to deprivation of optimal oxygen supply and increased cellular proliferation and metabolic rate. Hypoxia causes the activation and stabilization of key transcription factors, the hypoxia-inducible transcription factors (HIFs). HIF-1α and HIF-2α control the expression of many tumorigenesis genes. HIFs promote tumor progression by stimulating angiogenesis, immunosuppression, EMT, and metabolic reprogramming, and by supporting malignant cell survival, motility, proliferation, plasticity, and enhancing treatment resistance and escape from a nutrient-deprived milieu. Hypoxia also upregulates the expression of PD-L1 in malignant cells and MDSCs via HIF-1α and HIF-2α. PD-L1, via binding to its receptor (PD-1), acts as a protumorigenic factor that induces immune tolerance within the tumor microenvironment and inhibits antitumor immune responses by suppressing activity of tumor-specific TILs. HIF inhibition synergizes with CPIs to block tumor development and progression. Further studies should determine how other factors in the tumor milieu, such as cytokines, chemokines, growth factors, hormones, and therapeutic agents, may interfere with the antitumor potential of a combination of HIF inhibitors and CPI therapy.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 3 X users
Referenced in 1 patents
45 readers on Mendeley
See more details